The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Vora P, Venugopal C, Salim SK, Tatari N, et al. Cell Stem Cell 2020 May 22. pii: S1934-5909(20)30147.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Vora P, Venugopal C, Salim SK, Tatari N, et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell 2020 May 22. pii: S1934-5909(20)30147.
PMID: 32464096